Okay besties, we’re talking biotech today — five stocks with real long-term potential, and I’m breaking it down like we’re chatting over iced lattes.
Let’s be real: biotech isn’t the sexiest topic on your feed. No one’s making TikToks about regulatory risk. But here’s the thing — if you want to build actual wealth, you eventually have to get comfortable with sectors that feel a little intimidating. And biotech, while famously volatile (these stocks can swing hard in both directions, and regulatory drama is always lurking), has some genuinely attractive long-term players right now. Biotech has performed well in 2026, but things can shift fast in this industry — which is exactly why I tell my coaching clients: never bet on a single year, bet on the business.
So here are five companies worth understanding if you’re thinking long haul. Grab your matcha, let’s go. 💗
1. Vertex Pharmaceuticals (VRTX) — The queen of her niche
Vertex has been the undisputed leader in cystic fibrosis medicines for years, and that core market remains a meaningful growth driver — with no major patent cliff expected for the next 10 years. Ten years, y’all. In investing terms, that’s basically stability.
But what I love even more? Vertex isn’t putting all its eggs in one basket. It’s making serious moves in kidney disease, with povetacicept (a treatment for IgA nephropathy) inching closer to approval, plus inaxaplin for APOL-1-mediated kidney disease in its Phase 3 pipeline. Add in several recent approvals whose sales should ramp up over the next few years, and you’ve got a dominant company actively diversifying.
Here’s what I’d do: if I wanted steady biotech exposure with a leader that isn’t standing still, Vertex would be on my shortlist. Dominance plus diversification? That’s the financial equivalent of a capsule wardrobe — classic, versatile, reliable.
2. Amgen (AMGN) — The diversified giant with a dividend
If Vertex is a specialist, Amgen is the girl with the fully stocked closet. In the third quarter, the company had 17 products delivering at least double-digit year-over-year sales growth — and 17 medicines with at least $1 billion in annual revenue run rate. That’s the kind of breadth that lets a company shrug off major patent cliffs (like the recent one for denosumab, a bone-disease medicine) without breaking a sweat.
The pipeline is deep too, featuring MariTide — a highly promising weight-loss medicine — which could extend its approved lineup even further. Oh, and Amgen is an excellent dividend stock, having increased its payout every single year since starting them in 2011. Growing income, every year, for over a decade? Yes please.
This is why I tell my coaching clients: dividends aren’t just for your grandma’s portfolio. Companies that consistently raise payouts tend to be financially disciplined, and that discipline compounds beautifully.
3. Gilead Sciences (GILD) — Expanding beyond its comfort zone
Gilead owns some of the best-selling HIV medicines on the planet — Biktarvy and Descovy for PrEP — and it’s still the bulk of the company’s sales. A recent approval for Bixlenvo, an HIV pill, just strengthened that position even further.
But here’s the exciting part: Gilead has been building out its oncology business, and its cancer drug pipeline is now larger than its HIV pipeline. As it launches new cancer products, the company’s lineup gets stronger and more diversified. Meanwhile, revenue and earnings growth remain strong, and the dividend is rock solid — payouts have grown 74.5% over the past decade.
Think of it like this: Gilead is the friend who built an incredible career in one field and then quietly started a thriving side business. Diversification isn’t just a budgeting principle, babes — it’s a business strategy, and Gilead is executing it well.
4. Exelixis (EXEL) — The small but scrappy one
Exelixis is the smallest name on this list, and honestly, it’s not the most popular biotech out there. But being under-the-radar isn’t a flaw. Exelixis has carved out a successful niche within the enormous, hyper-competitive oncology market. Its flagship medicine, Cabometyx, has earned multiple indications across multiple cancer types.
Now, the honest caveat: Cabometyx will likely face generic competition in the U.S. by early 2030. But Exelixis saw this coming and prepared — it could win approval for zanzalintinib, an investigational colorectal cancer drug, next year, and it’s targeting additional indications while developing new cancer medicines.
Here’s what I’d do: if I wanted a smaller, growth-oriented position in my portfolio, this is the profile I’d look for — a company that knows its niche and has a clear plan for what’s next. Smaller companies carry more risk, so this is where position sizing matters. Never let one small stock carry your whole portfolio, okay?
5. Regeneron Pharmaceuticals (REGN) — The comeback story
Y’all know I love a good comeback. Regeneron has faced stiff competition for Eylea, its eye-disease medicine, which hurt financial results in recent years. But the company is putting that chapter behind it — revenue and earnings growth have rebounded, largely thanks to a new formulation of Eylea and Dupixent, its eczema medicine. Both are central to the company’s long-term plans.
Yes, Dupixent may hit a patent cliff early next decade, but Regeneron is likely to defend its turf — including developing a high-dose formulation of Dupixent. It also has an attractive pipeline to diversify, including promising weight-loss candidates. The comeback may just be getting started, and it’s still time to buy the stock.
There’s a money lesson here too: even great companies hit rough patches. What matters is whether they adapt. A setback isn’t a full story — it’s one chapter.
The Jessie takeaway ✨
Biotech is volatile, full stop. But volatility isn’t the enemy — being uninformed is. These five companies (Vertex, Amgen, Gilead, Exelixis, Regeneron) each bring something different to the table: dominance, diversification, dividend growth, niche strength, and a turnaround. That variety is exactly how thoughtful investors think — not chasing what’s hot, but building a portfolio with intention.
If biotech is new to you, start small, do your homework, and only invest money you won’t need for years. Wealth-building is a marathon in cute shoes, not a sprint.
If this breakdown made biotech feel a little less scary, slide into my DMs and tell me which stock you’re researching first — or join my mailing list so you never miss a money breakdown. Let’s get you investing smarter, on your own terms. 💸
